BLK enters its July 15 earnings date down 8% over the past month and 5% on the week, with the options market — which had been unusually constructive just days ago — now pulling back toward neutral.
The shift in options positioning is the most notable change since the last note. The put/call ratio has dropped further to 0.96, now nearly 1.8 standard deviations below its 20-day average of 1.16. That reading sits close to the 52-week low of 0.87, suggesting options traders are still leaning toward calls rather than protection. But the move is worth watching in context: a week ago the ratio was at 1.04 and trending lower; the pace of that shift has slowed. The directional bet in options is still there, but it looks less aggressive than it did heading into last week. Cost to borrow has also moved — up 29% on the week to 0.41%, though still negligible in absolute terms. Borrow availability remains effectively uncapped. None of this points to a build in structural short pressure; the lending market is simply too loose for that story to hold.
Short interest itself is a sideshow. At 1.3% of the free float, and up just 2.3% on the week, the short base has barely shifted. The month-on-month rise of 13.5% sounds dramatic until you see the absolute level — around two million shares — which is tiny relative to BlackRock's overall float. There is no meaningful squeeze dynamic here, and the ORTEX short score of 30.9 sits comfortably in territory that reflects low short-seller conviction.
The Street's view is far more bullish than the stock's recent behaviour would imply, though analyst activity has been limited since April. Following a strong Q1 beat, most major houses raised targets: Goldman Sachs lifted to $1,313, Morgan Stanley moved to $1,393, and UBS went to $1,270, all maintaining positive ratings. On June 26, Morgan Stanley's Mike Cyprys raised his target again to $1,430, keeping Overweight — the most recent action and a meaningful data point given the timing, just three weeks before the Q2 print. JP Morgan sits on the other side at Neutral with a $1,128 target. The consensus mean of $1,252 implies roughly 30% upside from the current $961 close — an unusually wide gap that reflects either significant Street confidence in the earnings recovery, or targets that haven't adjusted to the recent drawdown. The forward earnings yield has drifted up to around 5.4% as the stock has sold off, and the PE multiple has contracted about 0.6 points over 30 days to 18.5x. The 12-month forward EPS growth score ranks in the 93rd percentile of the universe — a factor signal that backs the bull case for those willing to look through near-term margin pressure. The dividend score ranks in the 97th percentile, though the dividend history in the dataset is stale and that ranking likely reflects yield consistency rather than recent increases.
On insider activity, the most recent data shows founder and CEO Laurence Fink sold approximately $35 million in stock on April 28 at prices around $1,050. President Rob Kapito sold a combined $9 million the day prior. Both trades were at prices well above where the stock trades now. These were likely pre-planned disposals rather than conviction sells — the significance scores are modest at 3 out of 10 — but the net 90-day insider activity runs to roughly $125 million in net selling, which is worth noting as context for how insiders were positioned ahead of the drawdown.
The past three earnings prints have all produced positive next-day moves of 2.3%–2.6%, with five-day reactions running in a similar range. The pattern has been consistently constructive — modest beats, modest bounces — making July 15 a test of whether the setup repeats or whether the price pressure of the past month reflects something the earnings release will need to address directly.
See the live data behind this article on ORTEX.
Open BLK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
